---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-23-000085"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:47:54.824343+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mineralys Q3 net loss $22.8M; cash $265.9M; Phase 3 Launch-HTN start on track for 2H2023, topline delayed to 2H2025

## Summary
- Net loss $22.8M (Q3 2023) vs $6.7M (Q3 2022); R&D expenses $22.5M, up from $6.1M.
- Cash, cash equivalents and investments $265.9M as of Sep 30, 2023; expected to fund operations through mid-2025.
- Advance-HTN topline data revised from 1H2024 to 2H2024 due to protocol amendment and enrollment curve.
- Phase 3 Launch-HTN trial remains on track to initiate in 2H2023; topline data now expected in 2H2025.
- Explore-CKD Phase 2 trial expected to start in 2H2023 with topline data in Q4 2024–Q1 2025.

## SEC filing metadata
- accession: 0001933414-23-000085
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/0001933414-23-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/mlys-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-23-000085
- JSON: https://secwatch.observer/filing/0001933414-23-000085.json
- Plain text: https://secwatch.observer/filing/0001933414-23-000085.txt

## Key facts
- Earnings Releases
  Mineralys Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/0001933414-23-000085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.